Alex M. DiNello
President and Chief Executive Officer
Alex DiNello brings over 30 years of experience in the medical industry, including 25 years of experience focusing on the spine and pain markets. He has extensive product, clinical development, and commercialization experience in the space and has brought over 60 products to market across the globe. Prior to joining Sollis Therapeutics, DiNello served as Chief Technology Officer, COO, and CEO respectively for Relievant Medsystems, Inc. achieving FDA clearance and commercialization for the Intracept System, a novel therapy for the treatment of chronic low back pain. Prior to Relievant, he served as vice president and general manager for Medtronic Kyphon where he was accountable for $400 million of worldwide business. He was promoted to the general manager position at Medtronic Kyphon from the position of vice president of research and development. Previous to that, he was vice president of research and development for Abbott Spine. He has served in various other positions in the medical device industry, including serving as vice president of strategic development and research and development at DePuy Spine, Johnson & Johnson.
Mr. DiNello holds a B.S. in Mechanical Engineering from University of California at Santa Barbara, an M.E. in Biomedical Engineering from University of Virginia and an MBA from Case Western Reserve University.
Bryan Jones PhD
Chief Operating Officer
Dr. Jones is a Co-Founder is the Chief Operating Officer of Sollis Therapeutics. He has more than 25 years of experience with Biotech and Specialty Pharmaceutical companies with specific expertise in Business and Product development. Prior to Sollis, he was a Vice President at Sorrento Therapeutics where he led the development of a neuraxially administered neuroablative compound for the treatment of chronic pain and neurogenic inflammation. While there, Dr. Jones led the creation of ARK Animal Health, an animal health subsidiary company.
Previously he was Chief Operating Officer at Sherrington Pharmaceuticals and Mt. Cook Pharma as well as Vice President at Kemia, Inc. Earlier in his career, Dr. Jones held executive roles in Business Development at Amylin Pharmaceuticals and in Research at Bristol-Myers Squib.
Dr. Jones received his B.S. in biology with a concentration in biochemistry from Iowa State University and holds a Ph.D. in genetics from the University of Washington.
Robert Daly MS, PhD
Vice President, Clinical Operations
Dr. Daly is a seasoned industry veteran with more than 20 years of relevant expertise in the pharmaceutical, biotech and CRO industries. His experience includes leadership roles in clinical operations, clinical research and product development. Prior to Sollis Dr. Daly successfully led many clinical programs, both nationally and globally, in a variety of therapeutic areas, resulting in several product approvals. His experience includes working in both large pharma as well as small biotech at companies such as CTI Biopharma, Dupont, SmithKline Beecham and for a CRO. He has authored more than 30 scientific, peer reviewed publications and has been a frequent presenter at major medical meetings.
Dr. Daly received his Ph.D. in pharmacology from the Medical College of Pennsylvania, a Master of Science in Molecular Genetics from Drexel University and a Bachelor of Arts degree in biology from Glassboro State College. He also has credentials from the Harvard Business School in Executive Education.